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S268 Poster Session Idays. While race/ethnicity (p\0.0001) and disease (p 5 0.01) were
associated with finding a donor, other variables (age, gender,
CIBMTR risk, CMV, KPS, socio-economic status) were not.
Among those with a donor, logistic regression modeling identified
increasing age (p 5 0.02), non-Caucasian race/ethnicity (p 5
0.002), and high CIBMTR risk (p 5 0.007) as associated with de-
creased odds for reaching HCT. Among 448 patients in the donor
group, 239 underwent HCT. Of those in the no donor group, a total
of 14 underwent double umbilical cord blood transplant (dUCBT).
In the primary ITT analysis, we studied outcome according to
donor vs. no donor status from time of search initiation using
a time-dependent Cox model. Compared to no donor, donor status
had reduced hazard for mortality (HR of 0.85, 95% CI 0.63 -1.2,
p 5 0.3). Accounting for interaction, those with KPS 90-100 and
donor had significantly reduced hazard (HR 0.59, 95% CI 0.38 -
0.90, p 5 0.02) compared to no donor. Secondary analyses exam-
ined outcome by treatment received: Those who received the
intended HCT in the donor group had significantly reduced hazard
(HR 0.64, 95%CI 0.46 – 0.89, p5 0.009) compared to no donor. In
a separate analysis, donor, dUCBT, and no donor/no UCBT were
treated as time-varying covariates, demonstrating significantly re-
duced hazard for donor vs. no donor (HR 0.57, 95% CI 0.43-
0.76, p 5 0.0001). No significant effect of matching (7/8 vs. 8/8)
was detected in any analyses. In total, these data provide new insight
into factors associated with unrelated donor identification according
to high-resolution typing methods, identify factors relevant to
reaching HCT among those with a suitable donor, and speak to
the efficacy of unrelated donor HCT.175
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Unrelated cord blood transplantation (CBT) is not widely used
to treat hemoglobinopathies (HGB) despite being the fastest grow-
ing stem cell source for unrelated hematopoietic cell transplanta-
tion (HCT). Published series show unfavorable disease-free
survival (Ruggeri et al. BBMT 2011) or were single institution
efforts (Jaing et al. BMT 2011). We analyzed the clinical outcome
for 101 HGB patients following CBT. The combination approach
to optimize nucleated cell (NC) dose of choosing CB products
manufactured by plasma depletion/reduction to maximize NC re-
covery, double grafts (whenever single CB had insufficient NC
dose), and post-thaw direct infusion were used by the 5 Asian
transplant centers (TCs) in this series that performed most of the
CBT. A CIBMTR on site-audited analysis was performed on 91
thalassemia and 10 sickle cell disease (SCD) patients transplanted
between 1999 and 2011 at 25 TCs in 6 countries using 114 CB
products processed by plasma depletion/reduction (88%) and 15
CB units processed by red cell reduction. 84% of the CB were in-
fused directly without post-thaw wash/reconstitution and 19% of
the transplants employed double CB grafts. Most TCs reported us-
age of no-TBI preparative regimens or ones that included Bu/Cy/
ATG. Graft failure rate at some TCs declined after switching from
oral busulfan to IV formulations, and 7 patients received a second
CBT. 24% of the transplants (24 patients/25 CB) were performed
at 18 U.S. TCs with the remainder (77 patients/104 CB) at 7 inter-
national TCs. 75% of the patients were Asian. Median follow-up
time was 711 days (range 2-2,877 days). Transplant characteristics:
median age 5.6 years (range 0.3-20); median patient weight 18.8 kg
(range 4-80); male 45%; HLA matches (intermediate resolution
HLA-A and -B and high resolution HLA-DRB1) of the CB used
in these patients: 6/6-23; 5/6-45; 4/6-54; 3/6-3; median pre-freezeTNC dose 9.4 x107/kg; median pre-freeze CD34+ dose 3.2 x105/
kg. The median times to myeloid and platelet engraftment were
17 days and 47 days, respectively. Of the 101 patients, 21 expired
before 180 days (20.8%); 26 prior to 1 year (25.7%) and 27 total
deaths (26.7%). To our knowledge, the current multi-center study
with 101 patients is the largest unrelated CBT series for HGB or
thalassemia. The data appear to support the notion that in the set-
ting of optimal cell dose, favorable overall and disease-free survival
may be achieved for unrelated CBT of HGB/thalassemia.
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Aim: To investigate the impact of HLA-DPA1 and -DPB1 mis-
match on clinical outcomes in a modern era of unrelated hematopoi-
etic stem cell transplantation (HSCT).
Methods: Retrospectively, 380 consecutive patients (median age
39, range 0.5-67 years) who underwent HSCT using HLA -A,
-B, and -DRB1 allele level-matched unrelated donors at our centre
during 1995-2010, were included in the study. Most patients un-
derwent HSCT in the treatment for hematological malignancies
(81%), whereas 7% and 12% of all patients were transplanted in
the treatment for non-hematological malignancies and non-malig-
nant disorders, respectively. HLA typing using PCR-SSP (Olerup-
SSP) or PCR-SSO on a Luminex platform (One Lambda) was
performed and revealed 55 HLA-DP (A1 and B1) matched and
325 mismatched donor pairs. HLA-DPA1 and HLA-DPB1 mis-
match was noted in 35% and 85% of all recipient donor pairs, re-
spectively.
